Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06427226 | Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity | recruiting | Phase 2 | 46 | Tanta UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06492759 | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05095207 | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 42 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05837455 | NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | recruiting | Phase 2 | 81 | Washington University School of MedicineOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810804 | A Phase IIa Study to Evaluate NBQ72S | recruiting | Phase 2 | 10 | Nantong Bencao Quadriga Medical Technology Co. Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07164976 | Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 86 | Nagoya City UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04841148 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer(PALAVY) | recruiting | Phase 2 | 96 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07227233 | Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.(AIM-BRIGHT) | recruiting | Phase 2 | 105 | University of California, San DiegoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07520760 | A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates(MBC-EA) | recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07112053 | A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 40 | University of WashingtonOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07492394 | Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05769010 | Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases | recruiting | Phase 2 | 150 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06365788 | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer(ABBICAR) | recruiting | Phase 2 | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07074106 | TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC(DespaTIL) | recruiting | Phase 2 | 40 | D'Or Institute for Research and EducationOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07455955 | Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile | recruiting | Phase 2 | 200 | Chinese University of Hong KongOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06450873 | Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06732336 | HER2-PET Imaging in HER2-low Breast Cancers | recruiting | Phase 1 / Phase 2 | 40 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03449238 | Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 41 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07371585 | Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management(TOP-REAL) | recruiting | Phase 2 | 300 | SOLTI Breast Cancer Research GroupOTHER | 3 | Mar 27, 2026 | clinicaltrials |
| NCT07498478 | Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment | recruiting | Phase 2 | 94 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07492589 | Photo-Acoustic and Ultrasonographic Mammoscope(PAUS) | recruiting | Phase 2 | 180 | Franciscus Gasthuis & Vlietland (Hospital)OTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07335081 | ctDNA in HER2+ EBC Neoadjuvant Treatment | recruiting | Phase 2 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05748834 | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | recruiting | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06568705 | Hypofractionated Online Adaptive Radiotherapy of Breast Cancer | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07294508 | A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 2 / Phase 3 | 706 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)(DUAL-NK-BC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05020574 | Microbiome and Association With Implant Infections | recruiting | Phase 2 | 200 | University of California, San FranciscoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07203729 | The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis | recruiting | Phase 2 | 184 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07471776 | Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05524584 | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | recruiting | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer(NEOTRIO-2) | recruiting | Phase 2 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01530373 | Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients | recruiting | Phase 2 | 110 | University of ArkansasOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06318897 | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06806930 | Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) | recruiting | Phase 2 | 90 | George Washington UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446452 | Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 37 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05325632 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | recruiting | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06679036 | A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 300 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT07342283 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer | recruiting | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials